Eukles Asset Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $148K | Sell |
1,169
-52
| -4% | -$6.85K | 0.06% | 86 |
|
|
2026
Q1 | $170K | Sell |
1,221
-23
| -2% | -$3.22K | 0.08% | 83 |
|
|
2025
Q4 | $153K | Sell |
1,244
-12,172
| -91% | -$1.48M | 0.06% | 84 |
|
|
2025
Q3 | $1.49M | Sell |
13,416
-168
| -1% | -$19.1K | 0.58% | 56 |
|
|
2025
Q2 | $1.51M | Sell |
13,584
-326
| -2% | -$34.7K | 0.62% | 52 |
|
|
2025
Q1 | $1.56M | Sell |
13,910
-116
| -0.8% | -$12K | 0.68% | 51 |
|
|
2024
Q4 | $1.3M | Sell |
14,026
-159
| -1% | -$14.3K | 0.55% | 57 |
|
|
2024
Q3 | $1.19M | Sell |
14,185
-251
| -2% | -$19.2K | 0.48% | 58 |
|
|
2024
Q2 | $990K | Sell |
14,436
-171
| -1% | -$11.4K | 0.43% | 57 |
|
|
2024
Q1 | $1.07M | Buy |
14,607
+389
| +3% | +$29.9K | 0.47% | 58 |
|
|
2023
Q4 | $1.15M | Sell |
14,218
-469
| -3% | -$36.5K | 0.54% | 55 |
|
|
2023
Q3 | $1.1M | Buy |
14,687
+85
| +0.6% | +$6.54K | 0.58% | 53 |
|
|
2023
Q2 | $1.13M | Buy |
14,602
+64
| +0.4% | +$5.1K | 0.58% | 52 |
|
|
2023
Q1 | $1.21M | Sell |
14,538
-61
| -0.4% | -$5.05K | 0.66% | 52 |
|
|
2022
Q4 | $1.25M | Buy |
14,599
+724
| +5% | +$57.3K | 0.73% | 50 |
|
|
2022
Q3 | $856K | Buy |
13,875
+298
| +2% | +$18.8K | 0.56% | 58 |
|
|
2022
Q2 | $839K | Buy |
13,577
+150
| +1% | +$9.29K | 0.53% | 57 |
|
|
2022
Q1 | $798K | Sell |
13,427
-1,113
| -8% | -$71.1K | 0.43% | 60 |
|
|
2021
Q4 | $1.06M | Sell |
14,540
-304
| -2% | -$20.9K | 0.51% | 58 |
|
|
2021
Q3 | $1.04M | Sell |
14,844
-41
| -0.3% | -$2.88K | 0.57% | 55 |
|
|
2021
Q2 | $1.02M | Buy |
14,885
+790
| +6% | +$52.8K | 0.57% | 57 |
|
|
2021
Q1 | $911K | Buy |
14,095
+97
| +0.7% | +$6.25K | 0.59% | 56 |
|
|
2020
Q4 | $816K | Buy |
13,998
+332
| +2% | +$20K | 0.56% | 55 |
|
|
2020
Q3 | $864K | Buy |
13,666
+128
| +0.9% | +$8.88K | 0.67% | 55 |
|
|
2020
Q2 | $1.04M | Buy |
13,538
+895
| +7% | +$68.6K | 0.89% | 45 |
|
|
2020
Q1 | $945K | Sell |
12,643
-640
| -5% | -$44.2K | 0.98% | 43 |
|
|
2019
Q4 | $863K | Sell |
13,283
-162
| -1% | -$10.6K | 0.7% | 52 |
|
|
2019
Q3 | $852K | Sell |
13,445
-43
| -0.3% | -$2.81K | 0.74% | 53 |
|
|
2019
Q2 | $911K | Sell |
13,488
-59
| -0.4% | -$3.88K | 0.79% | 52 |
|
|
2019
Q1 | $881K | Buy |
13,547
+67
| +0.5% | +$4.45K | 0.8% | 52 |
|
|
2018
Q4 | $843K | Buy |
+13,480
| New | +$942K | 0.88% | 50 |
|
Other funds holding GILD
Eukles Asset Management's GILD Position: Q2 2026 in Review
Eukles Asset Management reduced its Gilead Sciences (GILD) stake by 4.3% in Q2 2026, selling an estimated $6.85K and leaving 1,169 shares worth $148K. The position accounts for 0.06% of the portfolio, ranked #86.
Eukles Asset Management first reported a position in GILD in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.56M in Q1 2025. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Eukles Asset Management held 1,169 shares of Gilead Sciences worth $148K as of Q2 2026.
- Eukles Asset Management sold 52 Gilead Sciences shares in Q2 2026, an estimated $6.85K.
- Gilead Sciences made up 0.06% of Eukles Asset Management's portfolio in Q2 2026, its #86 holding.
- Eukles Asset Management first reported a position in Gilead Sciences in Q4 2018 and has held it in 31 quarters since.
- Eukles Asset Management's Gilead Sciences position peaked at $1.56M in Q1 2025.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Eukles Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.